Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy

Oncology

Volumn 76, Issue 5, 2009, Pages 355-362

  Li, Jian ^a   Chen, Ping ^a   Dai, Chun Hua ^a   Li, Xiao Qin ^a   Bao, Quan Lei ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

Advanced lung cancer; Combination chemotherapy; Comorbidities; Elderly cancer patients; Non small cell lung cancer; Prognostic factor, response; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; ELDERLY CARE; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL RECORDS; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 62849115084     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210024     Document Type: Article

References (30)

1. Bunn PA Jr, Lilenbaum R: Chemotherapy for elderly patients with advanced non-smallcell lung cancer. J Natl Cancer Inst 2003; 95: 341-343.
2. Martins SJ, Pereira JR: Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol 1999; 22: 453-457.
3. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000; 18: 623-631.
4. Kelly K, Crowlely J, Bunn PA Jr, et al: Randomized phase II trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced nonsmall- cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001; 19: 3210-3218.
5. Balducci L, Exterman M: Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 1997; 80: 1317-1322.
6. Balducci L, Extermann M: Management of cancer in the older person: a practical approach. Oncologist 2000; 5: 224-237.
7. Gridelli C, Perrone F, Gallo C, et al: Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced nonsmall- cell lung cancer: a two-stage phase II study. Eur J Cancer 1997; 33: 392-397.
8. Baccheri G, Ferrigno D: Vinorelbine in elderly patients with inoperable non-small cell lung carcinoma: a phase II study. Cancer 2000; 88: 2677-2685.
9. Altavilla G, Adamo V, Buemi B, et al: Gemcitabine as single agent in the treatment of elderly patients with advanced non-small cell lung cancer. Anticancer Res 2000; 20: 3675-3678.
10. Ricci S, Antonuzzo A, Galli L, et al: Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: multicenter phase II study. Lung Cancer 2000; 27: 75-80.
11. Gridelli C, Cigolari S, Gallo C, et al: Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly study (MILES) randomized trial. Lung Cancer 2001; 31: 277-284.
12. Chen YM, Perny RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J: A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) nonsmall- cell lung cancer patients aged 80 or older. Lung Cancer 2003; 40: 221-226.
13. Langer CJ, Manola J, Bernado P, et al: Cisplatin- based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.
14. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98: 779-788.
15. Lilenbaum RC, Herndon J, List M, et al: Single- agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and leukaemia group B (study 9730). J Clin Oncol 2005; 23: 190-196.
16. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced nonsmall- cell lung cancer. J Clin Oncol 2000; 18: 2529-2536.
17. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
18. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15: 2996-3018.
19. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
20. Repetto L, Venturino A, Fratino L, et al: Geriatric oncology: a clinical approach to the older patients with cancer. Eur J Cancer 2003; 39: 870-880.
21. Beretta GD, Michetti G, Belometti MO, et al: Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 2000; 83: 573-576.
22. Berardi R, Porfiri E, Scartozzi, et al: Elderly patients with advanced non-smell cell lung cancer: a phase II study with weekly cisplatin and gemcitabine. Oncology 2003; 65: 198-203.
23. Ohe Y, Niho S, Kakinum R, et al: A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004; 15: 45-50.
24. Feliu J, López Gfimez L, MadroŇal C, et al: Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer 1999; 86: 1463-1469.
25. Maione P, Perrone F, Gallo C, et al: Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study. J Clin Oncol 2005; 23: 6865-6872.
26. Yancik R, Ganz PA, Varricchio CG, Conley B: Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 2001; 19: 1147-1151.
27. Fossella F, DeVore R, Kerr R, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-2362.
28. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
29. Weiss GJ, Langer C, Rosell R, et al: Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 4405-4411.
30. Altunday O, Stewart DJ, Fossella FV, et al: Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2007; 2: 141-146.